ProMIS Neurosciences Inc. (PMN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PMN SEC filings page.
This page shows ProMIS Neurosciences Inc. (PMN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The numbers show a research-led operation whose spending accelerated while financing replaced much of the cash consumed by operations.
In FY2024, net income was positive at$2.8M while operating income was negative at-$16.8M , indicating reported profit depended on items below core operations. By FY2025, a net loss of$39.7M accompanied operating loss of$40.2M , removing that offset and making earnings quality easier to read.
Research spending rose from
FY2025 financing inflows of
Financial Health Signals
ProMIS Neurosciences Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ProMIS Neurosciences Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
ProMIS Neurosciences Inc. reported a net loss of $39.7M while operations used $28.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ProMIS Neurosciences Inc. reported -$11.7M in net income in Q2 2026. This represents a decrease of 15.9% from the same quarter a year earlier. Against the prior quarter it is down 42.3%.
ProMIS Neurosciences Inc. earned -$1.28 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 1.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
ProMIS Neurosciences Inc. held $53.4M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
ProMIS Neurosciences Inc.'s ROE was -23.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 10.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
ProMIS Neurosciences Inc. invested $9.5M in research and development in Q2 2026. This represents an increase of 8.8% from the same quarter a year earlier. Against the prior quarter it is up 36.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
PMN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $9.5M+8.8% | $7.0M+27.6% | N/A | $9.8M+282.1% | $8.7M+438.2% | $5.5M+157.3% | N/A | $2.6M+124.5% |
| SG&A Expenses | $2.7M+91.3% | $1.7M-16.1% | N/A | $2.0M+4.4% | $1.4M+31.9% | $2.0M+28.5% | N/A | $1.9M+36.0% |
| Operating Income | -$12.3M-20.4% | -$8.6M-15.9% | N/A | -$11.8M-165.0% | -$10.2M-275.3% | -$7.5M-102.9% | N/A | -$4.4M-76.2% |
| Net Income | -$11.7M-15.9% | -$8.2M-12.2% | N/A | -$11.6M-224.8% | -$10.1M-285.6% | -$7.3M-102.1% | N/A | $9.3M+492.9% |
| EPS (Basic) | -$1.28+82.4% | -$1.26+76.1% | -$21.83-956.1% | -$0.24-177.4% | -$7.26-5484.6% | -$5.27-2673.7% | $2.55+2933.3% | $0.31+263.2% |
| EPS (Diluted) | -$1.28 | -$1.26 | -$21.83 | -$0.24 | -$7.26 | -$5.27 | $2.50+2877.8% | $0.31 |
| Diluted Shares (Avg) | 9M | 7M | N/A | 49M | 1M | 1M | N/A | 30M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
PMN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $56.7M+496.2% | $67.4M+394.0% | $9.2M-51.4% | $21.5M-12.5% | $9.5M+574.6% | $13.6M+284.6% | $18.9M+38.9% | $24.5M+37.1% |
| Current Assets | $56.7M+496.2% | $65.6M+380.8% | $9.2M-51.4% | $21.5M-12.5% | $9.5M+574.6% | $13.6M+284.6% | $18.9M+38.9% | $24.5M+37.3% |
| Cash & Equivalents | $53.4M+1084.7% | $63.8M+662.9% | $6.1M-54.0% | $15.4M-28.5% | $4.5M+354.4% | $8.4M+235.0% | $13.3M+5.5% | $21.5M+27.7% |
| Short-Term Investments | $34K+2.1% | $34K+2.1% | $34K+2.1% | $33K+2.1% | $33K+2.1% | $33K+2.1% | $33K+2.1% | $32K+1.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.3M-26.3% | $6.7M+60.3% | $10.4M+330.9% | $12.3M-28.8% | $9.9M+168.3% | $4.2M+20.3% | $2.4M-75.4% | $17.2M+55.0% |
| Current Liabilities | $7.2M-26.5% | $6.6M+63.1% | $10.4M+369.3% | $12.2M+363.4% | $9.8M+209.7% | $4.1M+53.3% | $2.2M-76.3% | $2.6M-73.3% |
| Non-Current Liabilities | $77K+13.6% | $79K-33.1% | $29K-85.8% | $60K-99.6% | $68K-86.8% | $119K-85.6% | $205K-60.3% | $14.6M+1050.0% |
| Total Equity | $49.4M+13012.1% | $60.7M+541.0% | -$1.3M-107.6% | $9.2M+26.3% | -$383K+83.2% | $9.5M+12185.2% | $16.5M+339.3% | $7.3M+7.7% |
| Retained Earnings | -$150.4M-39.0% | -$138.7M-41.4% | -$130.4M-43.8% | -$119.7M-32.4% | -$108.2M-8.5% | -$98.0M-1.0% | -$90.7M+3.0% | -$90.4M-0.6% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PMN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.4M-169.4% | -$12.4M-151.3% | -$9.3M-6.5% | -$10.1M-50.7% | -$3.9M-156.2% | -$4.9M+52.1% | -$8.7M-131.9% | -$6.7M-180.7% |
| Stock-Based Compensation | $409K+92.9% | $189K-22.8% | N/A | $197K+62.9% | $212K+1077.9% | $245K+285.8% | N/A | $121K-9.8% |
| Financing Cash Flow | $0 | $70.1M | -$1-100.0% | N/A | N/A | N/A | $470K+192.0% | $27.2M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
PMN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -23.7% | -13.6%+64.0pp | N/A | -126.0%-253.6pp | N/A | -77.6%+4637.3pp | N/A | 127.5%+162.5pp |
| Return on Assets | -20.7%+85.7pp | -12.2%+41.6pp | N/A | -54.0%-91.8pp | -106.4%+79.7pp | -53.8%+48.6pp | N/A | 37.8%+51.0pp |
| Current Ratio | 7.85+6.9x | 9.92+6.6x | 0.88-7.6x | 1.76-7.5x | 0.97+0.5x | 3.36+2.0x | 8.52+7.1x | 9.30+7.5x |
| Debt-to-Equity | 0.15 | 0.11-0.3x | N/A | 1.34-1.0x | N/A | 0.44-44.6x | 0.15+0.1x | 2.37+0.7x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.88), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ProMIS Neurosciences Inc. PMN | FY2025 | N/A | -$39.7M | N/A | $86.2M | — |
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $240.8M | 67/100 |
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $1.7M | 42/100 |
| Lisata Therapeutics, Inc. LSTA | FY2025 | $170K | -$17.0M | N/A | $13.0M | — |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $18.6M | — |
Where ProMIS Neurosciences Inc. Ranks
Frequently Asked Questions
Is ProMIS Neurosciences Inc. profitable?
No, ProMIS Neurosciences Inc. (PMN) reported a net income of -$39.7M in fiscal year 2025.
What is ProMIS Neurosciences Inc.'s operating cash flow?
ProMIS Neurosciences Inc. (PMN) recorded an outflow of $28.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ProMIS Neurosciences Inc.'s total assets?
ProMIS Neurosciences Inc. (PMN) had $9.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ProMIS Neurosciences Inc. spend on research and development?
ProMIS Neurosciences Inc. (PMN) invested $33.4M in research and development during fiscal year 2025.
What is ProMIS Neurosciences Inc.'s current ratio?
ProMIS Neurosciences Inc. (PMN) had a current ratio of 0.88 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ProMIS Neurosciences Inc.'s return on assets (ROA)?
ProMIS Neurosciences Inc. (PMN) had a return on assets of -432.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ProMIS Neurosciences Inc.'s P/E ratio?
ProMIS Neurosciences Inc. (PMN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $86.2M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ProMIS Neurosciences Inc.'s price-to-sales ratio?
ProMIS Neurosciences Inc. (PMN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $86.2M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ProMIS Neurosciences Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ProMIS Neurosciences Inc. (PMN) held $6.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.1M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is ProMIS Neurosciences Inc.'s debt-to-equity ratio negative or not reported?
ProMIS Neurosciences Inc. (PMN) has negative shareholder equity of -$1.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ProMIS Neurosciences Inc.'s Piotroski F-Score?
ProMIS Neurosciences Inc. (PMN) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ProMIS Neurosciences Inc.'s earnings high quality?
ProMIS Neurosciences Inc. (PMN) reported a net loss of $39.7M while operations used $28.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.